Diligence memo · auto-generated · as of July 2, 2026

iVeena Delivery Systems, Inc.

iVeena Delivery Systems, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

iVeena Delivery Systems, Inc. operates in Pharmaceuticals, based in Salt Lake City.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

iVeena Delivery Systems, Inc. has raised $5.6M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.5M on 2017-07-01.

Most recent recorded round closed around 2019-05-29.

Valuation (modeled)modeled

Provath models iVeena Delivery Systems, Inc. at approximately $81M (range $1.6M–$636M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.42× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era. Within the normal band (142% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 7.1 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.2× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 44% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 51% of those peers.

Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., Metuchen Pharmaceuticals, LLC.

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.